An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Nature

Volumn 435, Issue 7042, 2005, Pages 677-681

  Oltersdorf, Tilman ^a   Elmore, Steven W ^b   Shoemaker, Alexander R ^b   Armstrong, Robert C ^a   Augeri, David J ^b   Belli, Barbara A ^a   Bruncko, Milan ^b   Deckwerth, Thomas L ^a   Dinges, Jurgen ^b   Hajduk, Philip J ^b   Joseph, Mary K ^b   Kitada, Shinichi ^c   Korsmeyer, Stanley J ^d,e   Kunzer, Aaron R ^b   Letai, Anthony ^e   Li, Chi ^f   Mitten, Michael J ^b   Nettesheim, David G ^b   Ng, ShiChung ^b   Nimmer, Paul M ^b   O'Connor, Jacqueline M ^b   Oleksijew, Anatol ^b   Petros, Andrew M ^b   Reed, John C ^c   Shen, Wang ^b   Tahir, Stephen K ^b   Thompson, Craig B ^f   Tomaselli, Kevin J ^a   Wang, Baole ^b   Wendt, Michael D ^b   Zhang, Haichao ^b   Fesik, Stephen W ^b   Rosenberg, Saul H ^b   more..

^a PFIZER INC   (United States)

^b ABBOTT LABORATORIES   (United States)

^c BURNHAM INSTITUTE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DISEASES; DRUG DOSAGE; MATHEMATICAL MODELS; NUCLEAR MAGNETIC RESONANCE; REGRESSION ANALYSIS; TOXICITY; TUMORS;

ANTI-CANCER THERAPEUTICS; APOPTOTIC PROCESS; CELL DEATH; CHEMO-RESISTANCE;

PROTEINS;

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; REGULATOR PROTEIN; SMALL MOLECULE INHIBITOR; UNCLASSIFIED DRUG; ABT-737; BIPHENYL DERIVATIVE; CYTOCHROME C;

MEDICINE;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; LYMPHOMA CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SOLID TUMOR; TUMOR GROWTH; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DISEASE MODEL; DRUG ANTAGONISM; LYMPHOMA; METABOLISM; MITOCHONDRION; NEOPLASM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; SMALL CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; SYNTHESIS; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CYTOCHROMES C; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; LYMPHOMA; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MITOCHONDRIA; MODELS, MOLECULAR; NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL RATE;

EID: 20444486559     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03579     Document Type: Article

References (30)

1. Daniel, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205-219 (2004).
2. Kirkin, V., Joos, S. & Zörnis, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 1644, 229-249 (2004).
3. Amundson, S. A. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101-6110 (2000).
4. Reed, J. C. Promise and problems of Bcl-2 antisense therapy. J. Natl Cancer Inst. 89, 988-990 (1997).
5. Letai, A., Sorcinelli, M. D., Beard, C. & Korsmeyer, S. J. Antiapoptotic Bcl-2 is required for maintenance of a model leukemia. Cancer Cell 6, 241-249 (2004).
6. Klasa, R. J., Gillum, A. M., Klem, R. E. & Frankel, S. R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12, 193-213 (2002).
7. Kutzki, O. et al. Development of a potent Bcl-XL antagonist based on α-helix mimicry. J. Am. Chem. Soc. 124, 11838-11839 (2002).
8. Tzung, S.-P. et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biol. 3, 183-191 (2001).
9. L. Chem. Biol. 11, 389-395 (2004).
10. Kitada, S. et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/ leukemia-2 proteins. J. Med. Chem. 46, 4259-4264 (2003).
11. Wang, J.-L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97, 7124-7129 (2000).
12. L. Nature Cell Biol. 3, 173-182 (2001).
13. Enyedy, I. J. et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 44, 4313-4324 (2001).
14. Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004).
15. Baell, J. B. & Huang, D. C. S. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharm. 64, 851-863 (2002).
16. Petros, A. M., Olejniczak, E. T. & Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644, 83-94 (2004).
17. Kelekar, A. & Thompson, C. B. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 8, 324-330 (1998).
18. Huang, D. C. & Strasser, A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 103, 839-842 (2000).
19. LBak peptide complex: Recognition between regulators of apoptosis. Science 275, 983-986 (1997).
20. Shuker, S. B., Hajduk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
21. Mao, H. et al. Rational design of diflunisal analogues with reduced affinity for human serum albumin. J. Am. Chem. Soc. 123, 10429-10435 (2001).
22. Letai, A. et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183-192 (2002).
23. Wei, M. C. et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730 (2001).
24. Fearon, E. R. et al. Karyoplasmic interaction selection strategy: A general strategy to detect protein-protein interactions in mammalian cells. Proc. Natl Acad. Sci. USA 89, 7958-7962 (1992).
25. Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097-1099 (1984).
26. Petros, A. M. et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl Acad. Sci. USA 98, 3012-3017 (2001).
27. Mao, H., Gunasekera, A. H. & Fesik, S. W. Expression, refolding, and isotopic labeling of human serum albumin domains for NMR spectroscopy. Protein Express. Purif. 20, 492-499 (2000).
28. Brunger, A. T. X-PLOR Version 3.1 (Yale Univ. Press, New Haven/London, 1992).
29. L. Anal. Biochem. 307, 70-75 (2002).
30. Wang, Z.-X. An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule. FEBS Lett. 360, 111-114 (1995).